{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T02:14:15Z","timestamp":1777083255171,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7315","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1038\/nature09454","type":"journal-article","created":{"date-parts":[[2010,9,7]],"date-time":"2010-09-07T12:54:41Z","timestamp":1283864081000},"page":"596-599","source":"Crossref","is-referenced-by-count":1588,"title":["Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma"],"prefix":"10.1038","volume":"467","author":[{"given":"Gideon","family":"Bollag","sequence":"first","affiliation":[]},{"given":"Peter","family":"Hirth","sequence":"additional","affiliation":[]},{"given":"James","family":"Tsai","sequence":"additional","affiliation":[]},{"given":"Jiazhong","family":"Zhang","sequence":"additional","affiliation":[]},{"given":"Prabha N.","family":"Ibrahim","sequence":"additional","affiliation":[]},{"given":"Hanna","family":"Cho","sequence":"additional","affiliation":[]},{"given":"Wayne","family":"Spevak","sequence":"additional","affiliation":[]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[]},{"given":"Gaston","family":"Habets","sequence":"additional","affiliation":[]},{"given":"Elizabeth A.","family":"Burton","sequence":"additional","affiliation":[]},{"given":"Bernice","family":"Wong","sequence":"additional","affiliation":[]},{"given":"Garson","family":"Tsang","sequence":"additional","affiliation":[]},{"given":"Brian L.","family":"West","sequence":"additional","affiliation":[]},{"given":"Ben","family":"Powell","sequence":"additional","affiliation":[]},{"given":"Rafe","family":"Shellooe","sequence":"additional","affiliation":[]},{"given":"Adhirai","family":"Marimuthu","sequence":"additional","affiliation":[]},{"given":"Hoa","family":"Nguyen","sequence":"additional","affiliation":[]},{"given":"Kam Y. J.","family":"Zhang","sequence":"additional","affiliation":[]},{"given":"Dean R.","family":"Artis","sequence":"additional","affiliation":[]},{"given":"Joseph","family":"Schlessinger","sequence":"additional","affiliation":[]},{"given":"Fei","family":"Su","sequence":"additional","affiliation":[]},{"given":"Brian","family":"Higgins","sequence":"additional","affiliation":[]},{"given":"Raman","family":"Iyer","sequence":"additional","affiliation":[]},{"given":"Kurt","family":"D\u2019Andrea","sequence":"additional","affiliation":[]},{"given":"Astrid","family":"Koehler","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Stumm","sequence":"additional","affiliation":[]},{"given":"Paul S.","family":"Lin","sequence":"additional","affiliation":[]},{"given":"Richard J.","family":"Lee","sequence":"additional","affiliation":[]},{"given":"Joseph","family":"Grippo","sequence":"additional","affiliation":[]},{"given":"Igor","family":"Puzanov","sequence":"additional","affiliation":[]},{"given":"Kevin B.","family":"Kim","sequence":"additional","affiliation":[]},{"given":"Antoni","family":"Ribas","sequence":"additional","affiliation":[]},{"given":"Grant A.","family":"McArthur","sequence":"additional","affiliation":[]},{"given":"Jeffrey A.","family":"Sosman","sequence":"additional","affiliation":[]},{"given":"Paul B.","family":"Chapman","sequence":"additional","affiliation":[]},{"given":"Keith T.","family":"Flaherty","sequence":"additional","affiliation":[]},{"given":"Xiaowei","family":"Xu","sequence":"additional","affiliation":[]},{"given":"Katherine L.","family":"Nathanson","sequence":"additional","affiliation":[]},{"given":"Keith","family":"Nolop","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2010,9,7]]},"reference":[{"key":"BFnature09454_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nature05610","volume":"446","author":"C Greenman","year":"2007","unstructured":"Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153\u2013158 (2007)","journal-title":"Nature"},{"key":"BFnature09454_CR2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949\u2013954 (2002)","journal-title":"Nature"},{"key":"BFnature09454_CR3","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nature04304","volume":"439","author":"DB Solit","year":"2006","unstructured":"Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358\u2013362 (2006)","journal-title":"Nature"},{"key":"BFnature09454_CR4","doi-asserted-by":"publisher","first-page":"5518","DOI":"10.1158\/0008-5472.CAN-10-0646","volume":"70","author":"H Yang","year":"2010","unstructured":"Yang, H. et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 70, 5518\u20135527 (2010)","journal-title":"Cancer Res."},{"key":"BFnature09454_CR5","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"363","author":"K Flaherty","year":"2010","unstructured":"Flaherty, K. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809\u2013819 (2010)","journal-title":"N. Engl. J. Med."},{"key":"BFnature09454_CR6","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1073\/pnas.0711741105","volume":"105","author":"J Tsai","year":"2008","unstructured":"Tsai, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041\u20133046 (2008)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature09454_CR7","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature08833","volume":"464","author":"G Hatzivassiliou","year":"2010","unstructured":"Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431\u2013435 (2010)","journal-title":"Nature"},{"key":"BFnature09454_CR8","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrd1496","volume":"3","author":"WH Koch","year":"2004","unstructured":"Koch, W. H. Technology platforms for pharmacogenomic diagnostic assays. Nature Rev. Drug Discov. 3, 749\u2013761 (2004)","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnature09454_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1479-5876-8-67","volume":"8","author":"JC Rubinstein","year":"2010","unstructured":"Rubinstein, J. C. et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J. Transl. Med. 8, 67 (2010)","journal-title":"J. Transl. Med."},{"key":"BFnature09454_CR10","doi-asserted-by":"publisher","first-page":"e4771","DOI":"10.1371\/journal.pone.0004771","volume":"4","author":"R Esteve-Puig","year":"2009","unstructured":"Esteve-Puig, R., Canals, F., Colome, N., Merlino, G. & Recio, J. A. Uncoupling of the LKB1-AMPK\u03b1 energy sensor pathway by growth factors and oncogenic BRAFV600E . PLoS ONE 4, e4771 (2009)","journal-title":"PLoS ONE"},{"key":"BFnature09454_CR11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.molcel.2008.12.026","volume":"33","author":"B Zheng","year":"2009","unstructured":"Zheng, B. et al. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol. Cell 33, 237\u2013247 (2009)","journal-title":"Mol. Cell"},{"key":"BFnature09454_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1479-5876-8-39","volume":"8","author":"JN S\u00f8ndergaard","year":"2010","unstructured":"S\u00f8ndergaard, J. N. et al. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific B-Raf inhibitor PLX4032. J. Transl. Med. 8, 39 (2010)","journal-title":"J. Transl. Med."},{"key":"BFnature09454_CR13","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1200\/JCO.2009.23.4823","volume":"27","author":"JP Arnault","year":"2009","unstructured":"Arnault, J. P. et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J. Clin. Oncol. 27, e59\u2013e61 (2009)","journal-title":"J. Clin. Oncol."},{"key":"BFnature09454_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3816\/CGC.2009.n.003","volume":"7","author":"Z Dubauskas","year":"2009","unstructured":"Dubauskas, Z. et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin. Genitourin. Cancer 7, 20\u201323 (2009)","journal-title":"Clin. Genitourin. Cancer"},{"key":"BFnature09454_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jaad.2006.10.032","volume":"56","author":"HH Kong","year":"2007","unstructured":"Kong, H. H. et al. Keratoacanthomas associated with sorafenib therapy. J. Am. Acad. Dermatol. 56, 171\u2013172 (2007)","journal-title":"J. Am. Acad. Dermatol."},{"key":"BFnature09454_CR16","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1200\/JCO.2008.20.3745","volume":"27","author":"GK Schwartz","year":"2009","unstructured":"Schwartz, G. K. et al. A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors. J. Clin. Oncol. 27, 3513 (suppl.), (2009)","journal-title":"J. Clin. Oncol."},{"key":"BFnature09454_CR17","doi-asserted-by":"publisher","first-page":"8503","DOI":"10.1200\/jco.2010.28.15_suppl.8503","volume":"28","author":"R Kefford","year":"2010","unstructured":"Kefford, R. et al. Phase I\/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J. Clin. Oncol. 28, 8503 (suppl.), (2010)","journal-title":"J. Clin. Oncol."},{"key":"BFnature09454_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","volume":"140","author":"SJ Heidorn","year":"2010","unstructured":"Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209\u2013221 (2010)","journal-title":"Cell"},{"key":"BFnature09454_CR19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature08902","volume":"464","author":"PI Poulikakos","year":"2010","unstructured":"Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427\u2013430 (2010)","journal-title":"Nature"},{"key":"BFnature09454_CR20","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ccr.2006.10.003","volume":"10","author":"S Courtois-Cox","year":"2006","unstructured":"Courtois-Cox, S. et al. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 10, 459\u2013472 (2006)","journal-title":"Cancer Cell"},{"key":"BFnature09454_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.molcel.2004.11.055","volume":"17","author":"MK Dougherty","year":"2005","unstructured":"Dougherty, M. K. et al. Regulation of Raf-1 by direct feedback phosphorylation. Mol. Cell 17, 215\u2013224 (2005)","journal-title":"Mol. Cell"},{"key":"BFnature09454_CR22","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1074-5521(99)80088-X","volume":"6","author":"CA Hall-Jackson","year":"1999","unstructured":"Hall-Jackson, C. A. et al. Paradoxical activation of Raf by a novel Raf inhibitor. Chem. Biol. 6, 559\u2013568 (1999)","journal-title":"Chem. Biol."},{"key":"BFnature09454_CR23","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nature08314","volume":"461","author":"T Rajakulendran","year":"2009","unstructured":"Rajakulendran, T., Sahmi, M., Lefrancois, M., Sicheri, F. & Therrien, M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461, 542\u2013545 (2009)","journal-title":"Nature"},{"key":"BFnature09454_CR24","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1073\/pnas.0900780106","volume":"106","author":"CA Pratilas","year":"2009","unstructured":"Pratilas, C. A. et al. V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl Acad. Sci. USA 106, 4519\u20134524 (2009)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature09454_CR25","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/nrm1743","volume":"6","author":"W Kolch","year":"2005","unstructured":"Kolch, W. Coordinating ERK\/MAPK signalling through scaffolds and inhibitors. Nature Rev. Mol. Cell Biol. 6, 827\u2013837 (2005)","journal-title":"Nature Rev. Mol. Cell Biol."},{"key":"BFnature09454_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ng1054","volume":"33","author":"PM Pollock","year":"2003","unstructured":"Pollock, P. M. et al. High frequency of BRAF mutations in nevi. Nature Genet. 33, 19\u201320 (2003)","journal-title":"Nature Genet."},{"key":"BFnature09454_CR27","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nature03890","volume":"436","author":"C Michaloglou","year":"2005","unstructured":"Michaloglou, C. et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720\u2013724 (2005)","journal-title":"Nature"},{"key":"BFnature09454_CR28","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","volume":"26","author":"EL Korn","year":"2008","unstructured":"Korn, E. L. et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J. Clin. Oncol. 26, 527\u2013534 (2008)","journal-title":"J. Clin. Oncol."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nature09454.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature09454","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature09454.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:47:02Z","timestamp":1684417622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature09454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":28,"journal-issue":{"issue":"7315","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["BFnature09454"],"URL":"https:\/\/doi.org\/10.1038\/nature09454","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.5306957.5260055","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.5306957.791052868","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.5306957.5295055","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}